The five genes from the gene expression signature with the highest discriminatory power to predict PFS on cabazitaxel were AGR2, FOXA1, DKK1, FAT1 and TMPRSS2. All genes used for the gene expression panel were selected based on expression and clinical relevance in prostate cancer. The gene discussed is AGR2; the disease is prostate cancer.